文献速递骨软组织肉瘤与黑色素瘤

晚期皮肤黑色素瘤中肿瘤浸润淋巴细胞过继治疗联合高剂量重组白细胞介素2的安全性:系统综述与Meta分析

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
PubMed 文献 · Ann Oncol · 2025-04-08

该系统综述与Meta分析检索PubMed至2024年2月29日,纳入12项高剂量白细胞介素2(HD-IL-2,≥600 000 IU/kg)研究、共670例有毒性信息的难治性晚期皮肤黑色素瘤患者,评估肿瘤浸润淋巴细胞(TILs)联合非清髓性淋巴清除化疗的安全性。发热性中性粒细胞减少的合并概率为60%(95%CI 36%~83%),严重免疫反应事件为4%(95%CI 1%~6%),感染和侵染类严重不良事件为8%(95%CI 4%~11%),报告9例致死性(5级)不良事件。

要点

  • 血液学毒性是最常见的不良事件,发热性中性粒细胞减少合并概率为60%(95%CI 36%~83%)。
  • 严重免疫反应事件合并概率为4%(95%CI 1%~6%),感染和侵染类严重不良事件为8%(95%CI 4%~11%)。
  • 共报告9例致死性(5级)不良事件,多述为与治疗无关或归因于NMA/HD-IL-2。

核心结论

  • TIL-ACT是黑色素瘤患者一种新获批且有前景的治疗,具有独特的毒性特征,目前可通过支持治疗进行管理,报告的毒性主要来自NMA-LD化疗和HD-IL-2,严重免疫反应事件风险低。
  • 持续系统记录和发表不良事件(即使罕见)及其与治疗组分的关系,对推动该领域发展至关重要。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed截至2024年2月29日。
  • 纳入12项HD-IL-2(≥600 000 IU/kg)研究,共670例有毒性信息的难治性晚期皮肤黑色素瘤患者。
  • 主要终点为3级或以上严重不良事件,安全性数据统一采用CTCAE v5.0编码。
  • 特别关注的不良事件组采用随机效应模型得出合并估计。

主要发现

  • 血液学毒性是最常见的不良事件。
  • 发热性中性粒细胞减少的合并概率为60%(95%CI 36%~83%)。
  • 严重「免疫反应」事件的合并概率为4%(95%CI 1%~6%)。
  • MedDRA系统器官分类「感染和侵染」中发生严重不良事件的概率为8%(95%CI 4%~11%)。
  • 共报告9例致死性(5级)不良事件,多述为与治疗无关或归因于NMA/HD-IL-2。

关键数值与推荐

  • HD-IL-2剂量阈值:≥600 000 IU/kg。
  • 主要终点:3级或以上严重不良事件,采用CTCAE v5.0编码。
  • 发热性中性粒细胞减少合并概率60%(95%CI 36%~83%)。
  • 严重免疫反应事件合并概率4%(95%CI 1%~6%)。
  • 感染和侵染类严重不良事件概率8%(95%CI 4%~11%)。

临床怎么用

  • TIL-ACT的毒性特征目前可通过支持治疗进行管理。
  • 报告的毒性主要来自NMA-LD化疗和HD-IL-2。
  • 严重免疫反应事件风险低。
  • 持续系统记录和发表不良事件(即使罕见)及其与治疗组分的关系,对推动该领域发展至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has consistently shown efficacy in advanced melanoma. Its combination with nonmyeloablative but lymphodepleting (NMA-LD) chemotherapy and high-dose interleukin 2 (HD-IL-2) inevitably lead to severe treatment-related adverse events. The systematic recording of the observed toxicities, which is the aim of the present meta-analysis, will further enhance the implementation and management of this treatment schema. MATERIALS AND METHODS: A comprehensive search was conducted in PubMed up to 29 February 2024. In this meta-analysis we focused on studies of treatment-refractory advanced cutaneous melanoma with TILs administered in combination with NMA-LD chemotherapy and HD-IL-2 (≥600 000 IU/kg). Our primary endpoint was severe adverse events (AEs) of grade 3 or higher. The safety data were consistently coded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Findings were synthesized using tables, while pooled estimates for groups of AEs of particular interest were derived from random effects models. RESULTS: A total of 12 HD-IL-2 studies of 670 patients with available toxicity information were included in this meta-analysis. Blood toxicities were identified as the most common AEs. In the frame of the formal meta-analysis, the pooled estimate of the probability of febrile neutropenia was 60% [95% confidence interval (CI) 36% to 83%]. The total pooled estimate for the probability of severe 'immunologic reaction' events, was 4% (95% CI 1% to 6%), while the respective probability for experiencing a severe AE in Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) category 'Infections and infestations' was 8% (95% CI 4% to 11%). In addition, in total, nine fatal (grade 5) AEs were reported, mostly stated as not attributed to the treatment or attributed to NMA/HD-IL-2. CONCLUSIONS: TIL-ACT, a new approved and promising therapy for melanoma patients, presents a distinctive toxicity profile that is currently manageable with supportive care methods, with reported toxicities mainly arising from NMA-LD chemotherapy and HD-IL-2, and a low risk of severe immunologic reaction events. Continued systematic recording and publication of AEs, even the rare ones, and their relation to treatment components, are essential to move the field forward.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Martín-Lluesma S, Dafni U, Vervita K, et al. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2025. PMID: 40210086. doi:10.1016/j.annonc.2025.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。